Ipilimumab + Oxaliplatin + Leucovorin + Fluorouracil + Irinotecan + Bevacizumab + Cetuximab + Nivolumab
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Colorectal Cancer
Conditions
Metastatic Colorectal Cancer
Trial Timeline
Aug 5, 2019 → Jun 10, 2026
NCT ID
NCT04008030About Ipilimumab + Oxaliplatin + Leucovorin + Fluorouracil + Irinotecan + Bevacizumab + Cetuximab + Nivolumab
Ipilimumab + Oxaliplatin + Leucovorin + Fluorouracil + Irinotecan + Bevacizumab + Cetuximab + Nivolumab is a phase 3 stage product being developed by Ono Pharmaceutical for Metastatic Colorectal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04008030. Target conditions include Metastatic Colorectal Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Colorectal Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04008030 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Colorectal Cancer